Tradestie Institutional Equity Comparison Engine

OBIO vs ICCC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ICCC Overall Edge

ICCC Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Valuation, Growth & Margin while OBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus ICCC at N/M Forward P/E and 15.2% operating margin (+11.5% YoY). In options structure, OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro) against ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ICCC
OBIO N/M vs ICCC N/M Fwd P/E
Growth & Margin Winner ICCC
Op Margin -195.4% vs 15.2% ยท YoY -89.4% vs +11.5%
Momentum & Technical Winner OBIO
1Y +70.3% vs +88.8% ยท 52W Pos 92% vs 91%
Options & Structure Winner OBIO
BREAKOUT (<1st %ile IV) vs UNCLASSIFIED (N/A IV)
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.12
-1.79% 1D
Market Cap $570.6M
1M Return +30.64%
1Y Return +70.33%
Forward P/E N/M
Unified AI Score
37.5 / 100 SELL
Tech 15.0 Fund 36.0 Flow 55.0 Mom 44.0
ICCC NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
1M Return +6.23%
1Y Return +88.76%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OBIO +70.33% ICCC +88.76% Spread: +18.43 pp (ICCC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period OBIO Revenue ICCC Revenue OBIO Op. Margin ICCC Op. Margin Margin Edge
FY2018 N/A $10M N/A -13.2% ICCC
FY2019 N/A $10M N/A -7.0% ICCC
FY2020 N/A $20M N/A -9.0% ICCC
FY2021 N/A $20M N/A 1.3% ICCC
FY2022 $0M $20M -924.3% -12.4% ICCC
FY2023 $0M $20M -1866.2% -32.9% ICCC
FY2024 $0M $30M -2437.5% -6.2% ICCC
FY2025 $30M $30M -154.7% 6.0% ICCC

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OBIO (2) vs ICCC (7)
Institutional Metric OBIO ICCC Criterion Row Winner
Market Capitalization Scale $570.6M $97.7M Larger Scale OBIO
Trailing P/E Ratio Valuation N/M 56.6x Lower Multiple ICCC
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -89.4% +11.5% Higher Growth ICCC
Operating Margin (TTM) Profitability -195.4% 15.2% Higher Margin ICCC
Net Profit Margin Profitability -182.5% 2.6% Higher Margin ICCC
Return on Equity (ROE) Capital Efficiency -182.3% 2.6% Higher ROE ICCC
52-Week Range Position Momentum 92% ($3โ€“$7) 91% ($5โ€“$12) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 1.15ฮฒ ยท 82% Vol 0.24ฮฒ ยท 46% Vol Lower Realized Risk ICCC
Unified Institutional Score Composite Signal 37.5 / 100 (SELL) 43.8 / 100 (HOLD) Higher Composite ICCC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OBIO vs ICCC Buy Guide
OBIO BREAKOUT
32d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ICCC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ICCC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OBIO nor ICCC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.